# Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants

> **NCT05858502** · NA · RECRUITING · sponsor: **Institut Pasteur** · enrollment: 90 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Blood sample collection
- **OTHER:** Saliva sample collection
- **OTHER:** Nasopharyngeal and nasal sample collection
- **OTHER:** Exhaled Breath Condensate (EBC)

## Key facts

- **NCT ID:** NCT05858502
- **Lead sponsor:** Institut Pasteur
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2026-03-15
- **Final completion:** 2026-06-18
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858502, "Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05858502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*